SCHEMBL1010096

SCHEMBL1010096

COc1ccc(C(=O)c2ccc(Br)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 1.00
MAPT P10636 2/20 1.00
LMNA P02545 2/20 1.00
MEN1 O00255 1/20 1.00
MAPK1 P28482 1/20 1.00
KMT2A Q03164 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
RXFP1 Q9HBX9 1/20 1.00
HPGD P15428 1/20 0.66
MAOA P21397 1/20 0.60
MAOB P27338 1/20 0.60
ALDH1A1 P00352 2/20 0.59
GAA P10253 1/20 0.59
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
NPC1 O15118 3/20 0.58
ATM Q13315 1/20 0.58
TUBB4A P04350 1/20 0.58
TUBB P07437 1/20 0.58
TUBA3C P0DPH7 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodomethane SCHEMBL26988000 0.96 RAB9A (0.92) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL21679502 0.94 RAB9A (0.89) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL9418310 0.89 RXFP1 (0.79) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL51509 0.89 RXFP1 (0.79) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL21679446 0.86 MAPT (0.74) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL29869740 0.86 MAPT (0.74) RAB9AMAPTLMNAMEN1MAPK1
Ethyne SCHEMBL8195983 0.85 RXFP1 (0.73) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL24538828 0.83 PARP10 (0.70) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL21246920 0.83 RXFP1 (0.70) RAB9AMAPTLMNAMEN1MAPK1
SCHEMBL14407949 0.83 PARP10 (0.70) RAB9AMAPTLMNAMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117623994-A Triphenylamine-based micromolecular anode interface layer material and preparation method thereof 南昌航空大学 2024-03-01 CN claimed
US-12595408-B2 Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses TOKUYAMA CORPORATION (JP) 2026-04-07 US disclosed
EP-4692072-A1 PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES TOKUYAMA CORPORATION (JP) 2026-02-11 EP disclosed
US-20250101294-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES TOKUYAMA CORPORATION (JP) 2025-03-27 US disclosed
WO-2025057814-A1 PHOTOCHROMIC COMPOSITION, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES 株式会社トクヤマ 2025-03-20 WO disclosed
WO-2025041624-A1 PHOTOCHROMIC COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES 株式会社トクヤマ 2025-02-27 WO disclosed
WO-2025028365-A1 PHOTOCHROMIC COMPOUND, PHENOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS 株式会社トクヤマ 2025-02-06 WO disclosed
EP-4471018-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES TOKUYAMA CORPORATION (JP) 2024-12-04 EP disclosed
WO-2024203790-A1 ADHESIVE SHEET, ADHESIVE SHEET WITH RELEASE FILM, LAMINATED BODY FOR IMAGE DISPLAY DEVICE, IMAGE DISPLAY DEVICE, AND ADHESIVE SHEET FOR COMPONENT FOR IMAGE DISPLAY DEVICE 三菱ケミカル株式会社 2024-10-03 WO disclosed
WO-2024202087-A1 PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES 株式会社トクヤマ 2024-10-03 WO disclosed
WO-2005012220-A9 CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR SMITHKLINE BEECHAM CORP (US) 2005-05-19 WO disclosed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US disclosed
WO-2005012220-A2 CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2005-02-10 WO disclosed
EP-0860433-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME KIRIN BREWERY (JP) 2002-07-03 EP disclosed
US-6143764-A ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS KIRIN BEER KABUSHIKI KAISHA (JP) 2000-11-07 US disclosed
EP-0860433-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 1998-08-26 EP disclosed
EP-0410359-B1 Substituted aminoalkoxy-benzene-derivatives HOFFMANN LA ROCHE (CH) 1994-01-26 EP disclosed
US-5214046-A Synergistic mixtures, inhibitors of sterol biosynthesis HOFFMANN-LA ROCHE INC. (US) 1993-05-25 US disclosed
US-5106878-A Synergistic effects with other fungicides HOFFMANN-LA ROCHE INC. (US) 1992-04-21 US disclosed
EP-0410359-A1 Substituted aminoalkoxy-benzene-derivatives F. HOFFMANN-LA ROCHE AG (CH) 1991-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD RAB9A 2847/4885MAPT 2279/4885LMNA 939/4885
US-12595408-B2 Photochromic compound, naphthol derivative, curable composition, optical article, lens, and eyeglasses CRYAA, CRYZ, CRY2 RAB9A 3057/4885MAPT 1481/4885LMNA 326/4885
US-20250101294-A1 PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES NAP1L1, CRYAA, CRYZ RAB9A 3845/4885MAPT 1071/4885LMNA 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.